Signaling pathways
-
F1832 Anti-Meflin Antibody (Tokai U. Patent Anti-Meflin)Summary: Anti-Meflin Antibody (Tokai U. Patent Anti-Meflin) -
F1833 Anti-Mesothelin Antibody (NIH patent anti-Mesothelin)Summary: Anti-Mesothelin Antibody (NIH patent anti-Mesothelin) -
F1834 Anti-MICB Antibody (U.Washington patent anti-MICB)Summary: Anti-MICB Antibody (U.Washington patent anti-MICB) -
F1835 Anti-MRC2/CD280 Antibody (Copenhagen Rigshospitalet patent anti-uPARAP)Summary: Anti-MRC2/CD280 Antibody (Copenhagen Rigshospitalet patent anti-uPARAP) -
F1836 Anti-MRC2/CD280 Antibody (Quark patent anti-ENDO 180)Summary: Anti-MRC2/CD280 Antibody (Quark patent anti-ENDO 180) -
F1837 Anti-MRC2/CD280 Antibody (Quark Patent Anti-Endo180)Summary: Anti-MRC2/CD280 Antibody (Quark Patent Anti-Endo180) -
F1838 Anti-MU5AC Antibody (Ensituximab-MMAE)Summary: Anti-MU5AC Antibody (Ensituximab-MMAE) -
F1839 Anti-NCAM1/CD56 Antibody (Lorvotuzumab-MMAE)Summary: Anti-NCAM1/CD56 Antibody (Lorvotuzumab-MMAE) -
F1840 Anti-oxLDL Antibody (Okayama U. patent anti-oxLDL)Summary: Anti-oxLDL Antibody (Okayama U. patent anti-oxLDL) -
F1841 Anti-PACAP38 Antibody (Lilly patent anti-PACAP)Summary: Anti-PACAP38 Antibody (Lilly patent anti-PACAP)